Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASER in Acute Flare of Crohn's Disease
NCT00417690Phase 2Terminated
- Sponsor
- Jacobus Pharmaceutical Company Inc.
- Start
- Jan 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing PASER with Placebo (2 arms). Primary endpoint: Response defined by reduction of CDAI score > 70 points at 4 weeks. Started Jan 2007; status: terminated.
02
Drugs
4-aminosalicylic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00417690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417690.